Advertisement

Topics

Standard Antiviral Drug Therapy and Adoptive Cellular Therapy in Treating Cytomegalovirus Infections in Patients After Donor Stem Cell Transplant

2014-08-27 03:13:59 | BioPortfolio

Summary

RATIONALE: Cytomegalovirus-specific adoptive cellular therapy and standard antiviral drug therapy may be effective in preventing and treating recurrent cytomegalovirus infections in patients who have undergone stem cell transplant. It is not yet known whether one type of adoptive cellular therapy is more effective than another type in preventing cytomegalovirus infections.

PURPOSE: This randomized phase III trial is comparing standard antiviral drug therapy with two types of adoptive cellular therapy in treating cytomegalovirus infections in patients after donor stem cell transplant.

Description

OBJECTIVES:

Primary

- To evaluate the potential clinical benefit of immunoprophylactic cytomegalovirus (CMV)-specific adoptive cellular therapy (ACT) and conventional antiviral drug therapy following T-cell-depleted allogeneic hematopoietic stem cell transplantation in terms of reduction in number of recurrent CMV reactivations.

Secondary

- To evaluate the effect of ACT on graft-versus-host disease (GVHD) incidence.

- To evaluate the effect of ACT on total days of CMV viremia and duration of antiviral drug therapy.

- To evaluate the effect of the selection process (hence cellular composition) of ACT on clinical and immunological endpoints.

- To evaluate the feasibility of centralized production and distribution of an ACT product.

OUTLINE: This is a multicenter study. Patients are stratified according to the availability of multimer selection process. Patients are randomized to 1 of 3* treatment arms. Treatment begins 27 days after allogeneic hematopoietic stem cell transplantation.

NOTE: *Patients for whom multimer selection process is not available are randomize to arm A or arm B.

- Arm A (Standard best available antiviral drug therapy alone): Patients receive standard best available antiviral drug therapy comprising ganciclovir IV twice daily and oral valganciclovir twice daily with or without foscarnet IV twice daily on days 27, 34, 41, 48, 55, 62, 69, 76, 83, 90, 97, 111, 139, 167, and 197.

- Arm B (Adoptive cellular therapy [ACT] and standard best available antiviral drug therapy): Patients receive allogeneic CMV-specific T cells, prepared using Gamma Catch Selection, IV on day 27. They also receive standard best available antiviral drug therapy as in arm A.

- Arm C (ACT and standard best available antiviral drug therapy): Patients receive allogeneic CMV-specific T cells, prepared using Multimer Selection, IV on day 27. They also receive standard best available antiviral drug therapy as in arm A.

After completion of study therapy, patients are followed periodically.

Study Design

Allocation: Randomized, Control: Active Control, Masking: Open Label, Primary Purpose: Supportive Care

Conditions

Breast Cancer

Intervention

allogeneic cytomegalovirus pp65-specific cytotoxic T lymphocytes, allogeneic cytomegalovirus-specific cytotoxic T lymphocytes, foscarnet sodium, ganciclovir

Location

UCL Cancer Institute
London
England
United Kingdom
WC1E 6DD

Status

Recruiting

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:13:59-0400

Clinical Trials [1504 Associated Clinical Trials listed on BioPortfolio]

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T c...

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory ...

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

The goal of this clinical research study is to learn if giving cytotoxic T lymphocytes (CTLs) can help control CMV when it reactivates (becomes active again) in patients who receive an all...

Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants

This study examines the immunologic and virologic effects of prophylactic CMV specific CTL in recipients of T cell depleted stem cell transplant (TCD SCT) at Duke University Medical Cente...

Virus-Specific Cytotoxic T-Lymphocytes (CTLs) for Adenovirus Infection Following an Allogeneic Stem Cell Transplant

The purpose of this study is to determine the largest and safest dose of Adenovirus (AdV)-specific cytotoxic T cells to be administered to individuals following a stem cell transplant, to ...

PubMed Articles [8845 Associated PubMed Articles listed on BioPortfolio]

Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.

Cytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred appro...

Cytomegalovirus infection among cord-blood allogeneic transplantation recipients: low incidence of cytomegalovirus events without high-dose valacyclovir prophylaxis.

Immunodominant cytomegalovirus-specific CD8+ T-cell responses in sub-Saharan African populations.

More than 90% of children in Africa are infected with cytomegalovirus (CMV) by the age of 12 months. However, the high-frequency, immunodominant CD8+ T-cell responses that control CMV infection have n...

Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients.

Allogeneic hematopoietic stem cell transplantation has proven curative for a range of malignant and nonmalignant disorders. However, the clinical success of this therapy is marred by the morbidity ass...

CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity.

Cytomegalovirus (CMV)-specific T-cells are crucial to prevent CMV disease. CMV seropositive recipients transplanted with stem cells from a CMV seronegative allogeneic donor (RD) may be at risk for CMV...

Medical and Biotech [MESH] Definitions

Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness.

An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.

A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.

Vaccines or candidate vaccines used to prevent infection with CYTOMEGALOVIRUS.

More From BioPortfolio on "Standard Antiviral Drug Therapy and Adoptive Cellular Therapy in Treating Cytomegalovirus Infections in Patients After Donor Stem Cell Transplant"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...


Searches Linking to this Trial